Search Results 321-330 of 7765 for SC

  1. Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects - Mayo Clinic

    The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

  2. Publications - Allison C. Rosenthal, D.O. - Mayo Clinic

    Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, ...

  3. Meniscus Injury - Sports Medicine Research - Mayo Clinic Research

    Faucett SC, Geisler BP, Chahla J, Krych AJ, Kurweil PR, Garner AM, Liu S, LaPrade RF, Pietzsch JB. Meniscus root repair vs meniscectomy or nonoperative ...

  4. Eddie L. Greene, M.D. - Doctors and Medical Staff - Mayo Clinic

    ... South Carolina. 1999 - 2000. FellowSouthern Society for Clinical ... MemberDiabetes Initiative of South Carolina, Medical University of South Carolina.

  5. Hematology - Clinical trials

    The purpose of this study is to demonstrate the efficacy non-inferiority between isatuximab SC and isatuximab IV in combination with pomalidomide and ...

  6. Paula Schiapparelli, Ph.D. - Mayo Clinic Faculty Profiles

    B.A.Sc. - Biology and Biochemistry University of Navarra. src="/-/media/kcms/gbs/research/images/. Clinical Studies. Learn about clinical trials that address ...

  7. Publications - John J. Lucido, III, Ph.D. - Mayo Clinic

    ... SC, Rule WG, Deufel CL, Foster MG. Development and Dosimetric Characterization of a Customizable Shield for Subtotal Skin Electron Beam Therapy. Adv Radiat ...

  8. Publications - Michael Gharacholou, M.D., M.S. - Mayo Clinic

    ... SC. Characteristics and outcomes of patients with peripheral artery disease undergoing endovascular revascularization: A community hospital perspective ...

  9. A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis - Mayo Clinic

    Participants will be randomized to receive either lebrikizumab or placebo subcutaneously (SC) every 4 weeks. Participation eligibility. Participant ...

  10. Publications - Kurt B. Angstman, M.D. - Mayo Clinic

    Angstman KB, Adamson SC, Furst JW, Houston MS, Rohrer JE. Provider satisfaction with virtual specialist consultations in a family medicine department. Health ...